China Universal Asset Management Co. Ltd. Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

China Universal Asset Management Co. Ltd. bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRNGet Rating) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 6,860 shares of the biotechnology company’s stock, valued at approximately $529,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Strs Ohio boosted its stake in BioMarin Pharmaceutical by 0.6% during the 4th quarter. Strs Ohio now owns 20,584 shares of the biotechnology company’s stock valued at $1,818,000 after acquiring an additional 132 shares during the last quarter. Spire Wealth Management lifted its position in shares of BioMarin Pharmaceutical by 59.7% in the 4th quarter. Spire Wealth Management now owns 377 shares of the biotechnology company’s stock worth $33,000 after buying an additional 141 shares during the last quarter. Veriti Management LLC lifted its position in shares of BioMarin Pharmaceutical by 4.0% in the 4th quarter. Veriti Management LLC now owns 3,981 shares of the biotechnology company’s stock worth $352,000 after buying an additional 153 shares during the last quarter. Vestmark Advisory Solutions Inc. lifted its position in shares of BioMarin Pharmaceutical by 3.9% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 4,352 shares of the biotechnology company’s stock worth $384,000 after buying an additional 165 shares during the last quarter. Finally, Evoke Wealth LLC lifted its position in shares of BioMarin Pharmaceutical by 9.1% in the 4th quarter. Evoke Wealth LLC now owns 2,071 shares of the biotechnology company’s stock worth $183,000 after buying an additional 173 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

A number of research firms recently weighed in on BMRN. Morgan Stanley raised shares of BioMarin Pharmaceutical from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $96.00 to $113.00 in a report on Monday, April 25th. Stifel Nicolaus restated a “buy” rating and set a $96.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, May 3rd. Wedbush restated a “hold” rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, June 24th. Jefferies Financial Group reiterated a “buy” rating and issued a $100.00 target price on shares of BioMarin Pharmaceutical in a report on Wednesday, May 4th. Finally, StockNews.com cut shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, May 30th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.46.

Shares of BMRN opened at $86.36 on Wednesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.28 and a current ratio of 4.88. The stock has a 50 day simple moving average of $79.28 and a 200 day simple moving average of $82.33. BioMarin Pharmaceutical Inc. has a 52-week low of $70.73 and a 52-week high of $94.20. The firm has a market capitalization of $15.98 billion, a PE ratio of 479.78, a P/E/G ratio of 1.78 and a beta of 0.33.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Rating) last issued its quarterly earnings data on Wednesday, April 27th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.16. BioMarin Pharmaceutical had a return on equity of 1.36% and a net margin of 2.09%. The business had revenue of $519.36 million during the quarter, compared to analyst estimates of $505.11 million. During the same period in the previous year, the firm earned $0.29 EPS. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post 0.94 EPS for the current fiscal year.

In other news, EVP George Eric Davis sold 15,347 shares of the stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $80.38, for a total value of $1,233,591.86. Following the completion of the sale, the executive vice president now owns 66,339 shares of the company’s stock, valued at approximately $5,332,328.82. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jeffrey Robert Ajer sold 1,308 shares of the stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $78.94, for a total value of $103,253.52. Following the completion of the sale, the executive vice president now directly owns 54,109 shares of the company’s stock, valued at approximately $4,271,364.46. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 97,763 shares of company stock valued at $8,097,160. Insiders own 1.75% of the company’s stock.

BioMarin Pharmaceutical Company Profile (Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Stories

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRNGet Rating).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.